Browse News by Year:
News Highlights:
WuXi PharmaTech Announces Third-Quarter 2010 Results
November 9, 2010 - View Full Article
IRONWOOD PHARMACEUTICALS PROVIDES THIRD QUARTER 2010 INVESTOR UPDATE
November 4, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its business activities for the third quarter of 2010. View Full Article
November 1, 2010 - View Full Article
Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
October 25, 2010 - View Full Article
October 21, 2010 - View Full Article
October 12, 2010 - View Full Article
September 15, 2010 - View Full Article
Tetraphase Named as One of the “Fierce 15” Biotech Companies of 2010
September 15, 2010 - View Full Article
Tetraphase Presents New Clinical and Preclinical Data for Novel AntibioticTP-434 at 2010 ICAAC
September 13, 2010 - View Full Article
Tetraphase to Present Extensive Data on Novel Broad Spectrum Antibiotic TP-434 at ICAAC
September 9, 2010 - View Full Article
Pfizer to Acquire FoldRx Pharmaceuticals
September 1, 2010 - FoldRx Focused on First-in-Class, Disease Modifying, Oral Therapeutics to Treat Disease Caused by Protein Misfolding View Full Article
ViewRay Secures Series C Financing
August 25, 2010 - ViewRay™, Inc., a privately held medical device company, has
secured $20 million in Series C financing led by new investor Siemens Venture Capital (SVC)
GmbH and joined by existing investors Aisling Capital, Fidelity Biosciences, Kearny Venture
Partners and OrbiMed Advisors. The funding is intended to move the ViewRay system, a unique
image-guided radiation therapy system now in the late stages of development, through the
process of commercialization and placement in major medical centers.* View Full Article
secured $20 million in Series C financing led by new investor Siemens Venture Capital (SVC)
GmbH and joined by existing investors Aisling Capital, Fidelity Biosciences, Kearny Venture
Partners and OrbiMed Advisors. The funding is intended to move the ViewRay system, a unique
image-guided radiation therapy system now in the late stages of development, through the
process of commercialization and placement in major medical centers.* View Full Article
July 15, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical,biotechnology, and medical device industries, with operations in China and the United States, today announced its preliminary financial highlights for second-quarter 2010. The full earnings results will be
announced on August 2, 2010. View Full Article
announced on August 2, 2010. View Full Article
July 14, 2010 - EnVivo Pharmaceuticals today announced at the Alzheimer’s Association 2010 International Conference on Alzheimer’s Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. View Full Article
Accuri Cytometers Completes $6 Million Series E Financing
July 12, 2010 - Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. View Full Article
June 30, 2010 - Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced today that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences. Proceeds from the financing will be used to fund Phase I and II development of V-101, the company’s lead investigational product for the treatment of rosacea, as well as a second product to treat various forms of bruising and purpura. View Full Article
Ikano Therapeutics in Exclusive Global Licensing Agreement for ITI-111
June 28, 2010 - Ikano Therapeutics Inc. (ITI) and Upsher-Smith Laboratories, Inc. announced today that they have concluded an exclusive global licensing agreement for ITI-111, ITI’s midazolam nasal spray. Under the terms of the agreement, Upsher-Smith will assume responsibility for all further development and commercialization of the product, which has received Orphan Drug status for the treatment of acute repetitive seizures in patients with epilepsy. View Full Article
Mersana Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology
June 23, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana’s Fleximer® platform. Mersana’s XMT-1001, a conjugate of Fleximer and camptothecin (CPT), is currently completing a Phase 1 study. View Full Article
June 17, 2010 - Transave announces positive Phase II results for once-daily ARIKACE™ in the treatment of cystic fibrosis patients who have pseudomonas lung infections, View Full Article
FoldRx Pharmaceuticals Secures $29 Million Financing
June 15, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced it has closed a $29 million financing to advance tafamidis to market. FoldRx has completed and previously reported the positive results of a pivotal trial of tafamidis as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening genetic neurodegenerative disease that affects thousands of patients worldwide. New investors Novo Ventures and Morgenthaler Ventures join existing investors HealthCare Ventures, Fidelity Biosciences, TPG Biotechnology, Alta Partners, and Novartis Venture Funds. View Full Article
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
June 1, 2010 - Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. View Full Article
Tetraphase Closes $45 Million Series C Financing
June 1, 2010 - Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing. Excel Venture Management led the round with participation from existing investors CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures. View Full Article
Transave Issues Key Composition of Matter Patent for Arikace (TM)
May 24, 2010 - Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE™ until October 1, 2026. View Full Article
NeuroTherapeutics Pharma Closes $43 Million Series B Financing and Adds Four New Investors
May 20, 2010 - NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co‐led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round. View Full Article
WuXi PharmaTech Announces First-Quarter 2010 Results
May 12, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for first-quarter 2010. View Full Article
Envivo Initiates Phase IIB Alzheimer's Disease Trial for EVP-6124
May 11, 2010 - EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer’s disease. The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer’s disease patients. View Full Article
Ironwood Pharmaceuticals Provides First Quarter 2010 Investor Update
May 11, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its business activities for the first quarter of 2010. View Full Article
Accuri and eBioscience Partner to Offer Complete Flow Cytometry Solutions
May 10, 2010 - Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement. The collaboration is designed to offer scientists a better and more comprehensive solution for their flow cytometry research needs, harnessing the cost-effectiveness, ease-of-use, performance capabilities and accessibility of the Accuri C6 Flow Cytometer® System with the market leading extensive line of high quality cytometer research reagents offered by eBioscience. View Full Article
FoldRx Pharmaceuticals Appoints Dr. Georges Gemayel as Executive Chairman
May 5, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that Georges Gemayel, Ph.D., has been appointed full time Executive Chairman of the company’s Board of Directors. Dr. Gemayel brings to the role more than 25 years of experience in successfully developing and commercializing drugs with several notable pharmaceutical and biotechnology companies. View Full Article
May 3, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today presented Phase 3 clinical trial results assessing the efficacy and safety of the investigational drug linaclotide in patients with chronic constipation (CC). Linaclotide is a guanylate cyclase type C (GC‐C) agonist in Phase 3 clinical development for the treatment of irritable bowel syndrome with constipation (IBS‐C) and CC. The data presented demonstrate that statistical significance versus placebo was achieved for the primary endpoint of 12‐week complete spontaneous bowel movement (CSBM) overall responder for each of the two doses studied in each trial. View Full Article
April 29, 2010 - Tetraphase Pharmaceuticals Inc., a biopharmaceutical company developing novel antibiotics based on proprietary synthetic chemistry technology, today announced that it will be participating in a session on drug discovery and development of novel treatments for drug-resistant infections, taking place at the 2010 BIO International Convention in Chicago. View Full Article
April 28, 2010 - LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from two Phase I studies of its norovirus virus-like particle (VLP) vaccine candidate were presented today at the 13th Annual Conference on Vaccine Research. Sponsored by the National Foundation of Infectious Diseases, the conference is being held in Bethesda, Maryland, from April 26-28, 2010. View Full Article
April 26, 2010 - Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion. View Full Article
FoldRx Pharmaceuticals Presents at the XII International Symposium on Amyloidosis Meeting
April 21, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that researchers presented results from the successful pivotal trial of tafamidis meglumine (tafamidis) at the XII International Symposium on Amyloidosis in Rome, Italy. Tafamidis, the company’s lead compound, is being investigated as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening neurodegenerative disease that affects an estimated 10,000 patients worldwide. View Full Article
April 20, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010. View Full Article
FoldRx Pharmaceuticals to Present at the American Academy of Neurology (AAN) Annual Meeting
April 14, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that researchers will present results from the successful pivotal trial of tafamidis meglumine (tafamidis) at the 62nd American Academy of Neurology (AAN) Annual Meeting in Toronto. Tafamidis, the company’s lead compound, is being investigated as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening neurodegenerative disease that affects an estimated 10,000 patients worldwide. View Full Article
April 13, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer. Mersana plans to initiate a Phase 1 clinical trial for XMT-1107 in the second quarter of 2010. XMT-1107 will be the company’s second oncology product to enter the clinic. Mersana’s XMT-1001, a conjugate of Fleximer and camptothecin (CPT), is currently completing a Phase 1 study. View Full Article
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
March 9, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for fourth-quarter and full-year 2009.
View Full Article
View Full Article
March 1, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinical services.
Underwriters Exercise Over-Allotment Option for Ironwood Pharmaceuticals' Initial Public Offering
February 16, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood’s Class A common stock. View Full Article
ViewRay Wins NorTech Innovation Award
February 16, 2010 - ViewRay, Inc., a privately held medical device company, has earned a NorTech Innovation Award for its advancements in radiation therapy technology for the treatment of cancer. ViewRay was honored for its unique combination of medical imaging and radiotherapy, which is designed to improve the effectiveness of cancer treatments. Radiation therapy is used to treat nearly two‐thirds of today’s cancer patients. View Full Article
January 19, 2010 - EnVivo Pharmaceuticals, Inc. has been awarded a research grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will fund research as part of the foundation’s Therapeutics Development Initiative that seeks new treatments for Parkinson’s disease. View Full Article
EnVivo Enters Phase 2B Trials for its EVP-6124 Compound in the Treatment of Schizophrenia
January 5, 2010 - EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe. View Full Article
1 Main Street, 13th Floor
Cambridge, MA 02142
Tel: (617) 231-2400
Fax: (617) 231-2425
Cambridge, MA 02142
Tel: (617) 231-2400
Fax: (617) 231-2425
Mailing Address
Fidelity Biosciences
82 Devonshire Street, EPC13A
Boston, MA 02109-3614
E-Mail: FidelityBiosciences@fmr.com
82 Devonshire Street, EPC13A
Boston, MA 02109-3614
E-Mail: FidelityBiosciences@fmr.com
© 2010 Fidelity Biosciences. All rights reserved.